Detalhe da pesquisa
1.
Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Alzheimers Dement
; 19(6): 2253-2264, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36450003
2.
An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia.
Br J Clin Pharmacol
; 87(3): 1098-1110, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32652643
3.
The potent BACE1 inhibitor LY2886721 elicits robust central Aß pharmacodynamic responses in mice, dogs, and humans.
J Neurosci
; 35(3): 1199-210, 2015 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25609634
4.
Modeling and simulations to confirm a controlled hypoglycemic stress test in healthy subjects is not associated with clinically significant QT prolongations.
Int J Clin Pharmacol Ther
; 52(9): 717-25, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24887333
5.
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.
Int Psychogeriatr
; 25(5): 707-19, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23257314
6.
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Clin Pharmacol Ther
; 113(6): 1258-1267, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36805552
7.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(2): e12404, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37388759
8.
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial.
J Alzheimers Dis Rep
; 7(1): 1015-1024, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37849628
9.
The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Drug Metab Dispos
; 40(10): 1945-52, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22789530
10.
QT effect of semagacestat at therapeutic and supratherapeutic doses.
Int J Clin Pharmacol Ther
; 50(4): 290-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22456300
11.
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
JAMA Neurol
; 79(10): 1015-1024, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094645
12.
Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.
J Alzheimers Dis Rep
; 6(1): 1-15, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243208
13.
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Alzheimers Dement (N Y)
; 7(1): e12112, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33614890
14.
Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia.
J Alzheimers Dis Rep
; 5(1): 321-336, 2021 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34113788
15.
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
J Med Chem
; 64(12): 8076-8100, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081466
16.
Cortisol response to individualised graded insulin infusions: a reproducible biomarker for CNS compounds inhibiting HPA activation.
Br J Clin Pharmacol
; 70(6): 886-94, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21175444
17.
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
J Clin Pharmacol
; 60(1): 107-116, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378968
18.
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.
J Clin Pharmacol
; 60(5): 586-594, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853995
19.
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
JAMA Neurol
; 77(2): 199-209, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31764959
20.
Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-ß.
J Alzheimers Dis
; 68(1): 137-144, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30741684